Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519906 | 0.86 | MEN1 (0.61) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL11449076 | 0.81 | XIAP (0.52) | MEN1KMT2ALMNAPDK1PDK2 | |
| SCHEMBL10710090 | 0.80 | MEN1 (0.79) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL2640639 | 0.80 | MEN1 (0.55) | MEN1KMT2AMAPK1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL8974695 | 0.79 | XIAP (0.51) | MEN1KMT2ALMNAPDK1PDK2 | |
| SCHEMBL10788223 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL11763698 | 0.77 | MEN1 (0.68) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL28503296 | 0.77 | TAAR1 (0.50) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL3612815 | 0.77 | MEN1 (0.67) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL30623497 | 0.77 | MEN1 (0.67) | MEN1KMT2AMAPK1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | claimed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | claimed |
| EP-1986996-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | Abiogen Pharma S.p.A. (IT) | 2008-11-05 | — | — | EP | claimed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | claimed |
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
| EP-1986996-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | Abiogen Pharma S.p.A. (IT) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | MEN1 2135/4885KMT2A 4634/4885MAPK1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.